Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FO33 CAR-T in CD33-Positive R/R AML
NCT07538713Phase 1Not yet recruiting
- Sponsor
- Qideng Pharmaceutical
- Start
- Jun 2026
- Primary completion
- May 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CD33 CAR-T in acute myeloid leukemia (AML), sponsored by Qideng Pharmaceutical. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 month and Complete Response rate at 3 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CD33 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07538713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538713.